• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Bullfrog AI Holdings Inc.

    4/1/26 4:42:42 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRG alert in real time by email
    424B5 1 form424b5.htm 424B5

     

    Filed pursuant to Rule 424(b)(5)

    Registration No. 333-281341

     

    PROSPECTUS SUPPLEMENT

    (To the Prospectus dated August 21, 2024, the Prospectus Supplement dated April 25, 2025, and the Prospectus Supplement dated November 7, 2025)

     

    BullFrog AI Holdings, Inc.

     

    Up to $4.3 million

     

    Of Shares of Common Stock

     

    This prospectus supplement (this “Prospectus Supplement No. 3”) amends and supplements certain information in our prospectus, dated August 21, 2024 (the “Base Prospectus”), the prospectus supplement dated April 25, 2025 (“Prospectus Supplement No. 1”), and the prospectus supplement dated November 7, 2025 (“Prospectus Supplement No. 2”, and together with Prospectus Supplement No. 1 and the Base Prospectus, the “ATM Prospectus”), each filed with the U.S. Securities and Exchange Commission as part of our registration statement on Form S-3 (333-281341), relating to the offer and sale of shares of our common stock, $0.00001 par value per share, from time to time pursuant to the terms of the At-the-Market Sales Agreement, or the Sales Agreement, with BTIG, LLC, or the sales agent. This Prospectus Supplement No. 3 should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus Supplement No. 3 is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus, and any future amendments or supplements thereto.

     

    Our common stock is listed on the Nasdaq Capital Market under the symbol “BFRG.” On April 1, 2026, the last reported sale price of our common stock was $1.62 per share. As of April 1, 2026, the aggregate market value of our outstanding common stock held by non-affiliates (the “Public Float”) was approximately $27.0 million based on 18,447,105 total shares of outstanding common stock, of which approximately 16.0 million shares were held by non-affiliates, and a price of $1.68 per share, which was the closing price of our common stock on the Nasdaq Capital Market on March 31, 2026, the highest closing sale price of our common stock on the Nasdaq Capital Market within 60 days prior to the date of this Prospectus Supplement No. 3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered in a public primary offering with a value exceeding more than one-third of our Public Float in any 12-calendar month period so long as our public float remains below $75.0 million. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date of this Prospectus Supplement No. 3, other than our offering of shares of common stock pursuant to the ATM Prospectus, having an aggregate value of approximately $4.7 million. As of April 1, 2026, one-third of the Public Float was equal to approximately $9.0 million, leaving approximately $4.3 million available for issuance under this Prospectus Supplement No. 3.

     

    Sales of our common stock, if any, under this Prospectus Supplement No. 3 will be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act. The sales agent is not required to sell any specific number of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

     

    If our public float increases such that we may sell additional amounts of common stock in excess of the aforementioned aggregate offering price under the Sales Agreement and the registration statement and ATM Prospectus, which this Prospectus Supplement No. 3 amends, we will file another prospectus supplement prior to making such additional sales in excess of the aforementioned aggregate offering price. In the event that our public float increases above $75.0 million, we will no longer be subject to the limit in General Instruction I.B.6 of Form S-3, and in such event, we will file another prospectus supplement prior to making additional sales above such limit.

     

     
     

     

    INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

     

    The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we file after the date hereof with the SEC will automatically update and supersede the information already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any future report or document that is not deemed filed under such provisions, after the date of this prospectus supplement and prior to the termination of this offering:

     

      ● Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 19, 2026;
         
      ● Current Reports on Form 8-K filed with the SEC on February 17, 2026, February 23, 2026, March 30, 2026, and April 1, 2026; and
         
      ● the description of our Common Stock, which is registered under Section 12 of the Exchange Act, contained in Exhibit 4.13 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 19, 2026, including any amendments or reports filed for the purpose of updating such description.

     

    Pursuant to Rule 412 under the Securities Act, any statement contained in a document incorporated or deemed to be incorporated by reference into this prospectus supplement will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus supplement modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.

     

    Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus supplement is delivered, a copy of the documents incorporated by reference into this prospectus supplement but not delivered with the prospectus supplement. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus supplement, at no cost by writing us at the following address: BullFrog AI Holdings, Inc., 325 Ellington Blvd., Unit 317, Gaithersburg, MD 20878, Attention: Secretary or by telephone by calling (240) 658-6710. Our website is located at www.bullfrogai.com. The reference to our website is intended to be an inactive textual reference and, except for the documents incorporated by reference as noted above, the information on, or accessible through, our website is not intended to be part of this prospectus supplement.

     

    You should rely only on the information incorporated by reference or provided in this prospectus supplement. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus supplement or in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus supplement or those documents. Nothing in this prospectus supplement shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item 2.02 or Item 7.01 of Form 8-K.

     

    We advise that there have been no material changes in our affairs that have occurred since the end of the latest fiscal period for which audited financial statements were included in the latest Form 10-K and that have not been described in a Form 10-Q or Form 8-K filed under the Exchange Act.

     

    This prospectus supplement is part of a registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the exhibits carefully for provisions that may be important to you.

     

    Our business and an investment in our common stock involve significant risks. These risks are described under the caption “Risk Factors” beginning on page S-6 of Prospectus Supplement No. 1 and in the documents incorporated by reference into this prospectus supplement.

     

    Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.

     

    BTIG

     

    The date of this prospectus supplement is April 1, 2026.

     

    2 

    Get the next $BFRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRG
    SEC Filings

    View All

    SEC Form 424B5 filed by Bullfrog AI Holdings Inc.

    424B5 - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    4/1/26 4:42:42 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    4/1/26 2:56:09 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    3/30/26 5:56:59 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hanson Jason David

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:16:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Enright William

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:14:44 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Elsey R Don

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:12:13 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder

    Commercial agreement serves as high-profile third party validation of BullFrog AI's proprietary capabilities Agreement utilizes BullFrog AI's end-to-end analytical AI platform to accelerate drug discovery and development program  GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue ("Customer"), to apply the Company's proprietary bfLEAP® platform to identify and prioritize

    3/30/26 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine

    GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today unveiled bfARENAS™, a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design, bolstering its end-to-end AI intelligence workflow. The Company will host a webinar in partnership with Xtalks Life Sciences on bfARENAS™ on March 27, 2026 at 11 a.m. ET. Organizations across biotech, pharma, and clinical research operate in high-uncertainty environments where timelines are lon

    3/25/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog to Host Webinar on New Precision AI Capability

    GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, will host a webinar in partnership with Xtalks Life Sciences, "Turning AI Recommendations into Clear, Defensible Decisions", about BullFrog AI's new precision AI capability on Friday, March 27, 2026 at 11 a.m. ET. The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision support layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools t

    3/11/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    12/27/24 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Announces Appointment of Chief Financial Officer

    GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer. "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and

    12/17/24 4:30:00 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

    GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery. Dr. Baldoni's career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, lea

    10/15/24 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Financials

    Live finance-specific insights

    View All

    BullFrog AI and GreenPower Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / April 26, 2024 / RedChip Companies will air interviews with BullFrog AI Holdings, Inc. (NASDAQ:BFRG) and GreenPower Motor Company Inc. (NASDAQ:GP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI: https://www.redchip.com/assets/access/bfrg_accessGreenPower: https://www.redchip.com/assets/access/gp_accessIn an exclusive interview, Vin Singh, CEO of BullFrog AI, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate u

    4/26/24 9:00:00 AM ET
    $BFRG
    $GP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessBullfrog AI: https://www.redchip.com/assets/access/bfrg_accessPaul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isoto

    10/27/23 9:00:00 AM ET
    $ASPI
    $BFRG
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedChip Launches 'Small Stocks, Big Money' Podcast

    New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

    8/2/23 12:45:00 PM ET
    $BFRG
    $LTRN
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology